Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-936557 induction and maintenance study in active ulcerative colitis
NL-OMON35771Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eldelumab in autoimmune colitis (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Clinical remission at Week 7. Started Nov 2011; status: active, not recruiting.
02
Drugs
eldelumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON35771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35771.